In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viagra's Phase IV Problems

Executive Summary

Shattering all previous barriers for impotence, sales of {Viagra} soared to nearly $100 million its first month out. Most industry analysts and drug company executives expect {Viagra} will be a blockbuster for many years to come, but there is a contrarian view. Contrarians argue that signs of problems are already beginning to emerge.

You may also be interested in...



Lilly Icos: A Complementary Alliance

The Lilly Icos joint venture for the erectile dysfunction drug Cialis has the markings of a complementary alliance. Though too soon to gauge its commercial efficacy, so far the deal is working because both parties view it as a vehicle to build value of the sort important to them.

NHS England And Vertex Strike “Lightening Quick” CF Kaftrio/Trikafta Deal

An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.

Nine More Years? Sandoz Loses Again On Enbrel Biosimilar

Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132892

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel